In both in vitro and in vivo studies, they were able to abolish B7-H3-induced L-OHP (oxaliplatin) and 5-FU resistance in CRC cell lines HCT-116 and RKO either by knockdown of HK2 expression or by 2-DG, a glycolytic inhibitor. The gene discussed is HK2; the disease is colorectal carcinoma.